A European Survey to Identify Challenges in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

[Background and Aims] Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe subtype, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and strongly associated with obesity and type 2 diabetes (T2D). This study sought to identify challenges t...

Descripción completa

Detalles Bibliográficos
Autores: Castera, Laurent, Alazawi, William, Bugianesi, Elisabetta, Caussy, Cyrielle, Federici, Massimo, Romero-Gómez, Manuel, Schattenberg, Jörn M., Basuroy, Ron, Prasad, Preethy, Estulin, Dmitry, Lazarus, Jeffrey V.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/390353
Acceso en línea:http://hdl.handle.net/10261/390353
https://api.elsevier.com/content/abstract/scopus_id/85214096193
Access Level:acceso abierto
Palabra clave:MASH
MASLD
Cross‐sectional study
Liver disease
Obesity
Type 2 diabetes
Descripción
Sumario:[Background and Aims] Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe subtype, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and strongly associated with obesity and type 2 diabetes (T2D). This study sought to identify challenges to the diagnosis, treatment and management of people living with MASLD and MASH and understand the key barriers to adopting relevant clinical guidelines.

Similares en LA Referencia